Myriad Genetics expects ~$400M cash on hand, no debt entering 2022

MYRIAD GENETICS INC

CEO Paul Diaz presented at 40th Annual J.P. Morgan Health Care Conference on Jan 11, 2022.
Company expects to start 2022 with approximately $400M in cash, cash equivalents, and marketable securities.
Preliminary unaudited FY2021 financial data not finalized; adjustments could be material.
Company reports no debt, highlighting strong liquidity position.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.